Chart Events
Performance Outlook
| Previous Close | 9.33 |
| Open | 9.42 |
| Bid | 9.44 x 1800 |
| Ask | 9.45 x 2900 |
| Day's Range | 9.33 - 9.58 |
| 52 Week Range | 8.42 - 12.40 |
| Volume | |
| Avg. Volume | 9,391,638 |
| Market Cap | 11.316B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | 5.47 |
| EPS (TTM) | 1.73 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | 0.48 (5.22%) |
| Ex-Dividend Date | Mar 08, 2023 |
| 1y Target Est | 15.63 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VTRS
Related Research
- Viatris Inc.Analyst Report: Viatris IncViatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer's Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has 37,000 employees.RatingFair ValueEconomic Moat4 months agoArgus Research
- Motley Fool
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
Healthcare spinoffs aren't normally seen as companies with strong growth potential. More likely than not, spinoffs stem from a division of a company that, while possibly profitable, is seeing slower growth. Embecta (NASDAQ: EMBC.V), Viatris (NASDAQ: VTRS) and GE Healthcare Technologies (NASDAQ: GEHC) are three of the bigger healthcare spinoffs in recent years.
- Motley Fool
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
How high of a dividend yield does a stock need to have to be considered a high-yield stock? Opinions vary. However, many investors would include any stock with a yield that's greater than that offered by 10-year U.
- Motley Fool
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.
